German Clients-Larazotide Acetate Peptide Capsules

Larazotide acetate (INN: Larazotide), a synthetic octapeptide (molecular formula: C₃₉H₅₆N₈O₁₀, CAS: 881851-50-9), has emerged as a groundbreaking therapeutic agent due to its unique mechanism of action: inhibiting zonulin, a protein that regulates intestinal tight junction (TJ) permeability. By stabilizing TJs, Larazotide prevents pathological paracellular transport of antigens and pathogens, offering applications across gastrointestinal disorders, viral infections, and even cancer.

It (formerly AT-1001) is a single-chain peptide with the sequence Val-Gly-Val-Ala-Pro-Gly-Trp-Pro-NH₂, engineered to mimic the TJ-stabilizing domain of Clostridium perfringens enterotoxin. Its molecular weight of 897 Da and zwitterionic nature enable oral bioavailability, a critical advantage for gastrointestinal therapies. Preclinical studies demonstrate its stability in acidic gastric environments and resistance to proteolytic degradation, ensuring targeted delivery to the small intestine.

Celiac disease is an autoimmune disorder triggered by gluten proteins (e.g., gliadin) in genetically susceptible individuals. Gluten activates intestinal zonulin, leading to TJ disassembly, increased permeability, and immune activation against transglutaminase 2 (tTG). Despite strict adherence to a gluten-free diet (GFD), up to 30% of patients experience persistent symptoms due to inadvertent gluten exposure or non-responsive disease.

● Mechanism of Action

Larazotide acetate competitively binds to the zonulin receptor (PAR2) on enterocytes, blocking zonulin-induced myosin light chain kinase (MLCK) activation. This prevents TJ protein redistribution (e.g., occludin, claudin-1) and actin cytoskeleton rearrangement, thereby tightening intercellular junctions.

In vitro studies: Larazotide acetate (1–10 μM) inhibits gluten-induced permeability increases in Caco-2 cell monolayers by 70–90%.

Ex vivo human trials: Duodenal biopsies from CD patients show normalized TJ structure after peptide treatment, with increased ZO-1 expression and reduced MLCK phosphorylation.

● Clinical Evidence

Phase 2 Trials: A 2007 study in 86 CD patients undergoing a 6-week gluten challenge (2.7 g/day) found that Larazotide acetate (1 mg TID) reduced gastrointestinal symptoms (e.g., bloating, diarrhea) by 50% compared to placebo (p<0.01). Urinary lactulose/mannitol ratios-a marker of intestinal permeability-normalized in 67% of treated patients versus 10% in controls.

Phase 3 CeliAction Study: In 342 CD patients on a GFD with persistent symptoms, the 1 mg TID dose showed a trend toward symptom improvement (p=0.06), with post-hoc analyses revealing significant benefits in patients with high baseline zonulin levels (>10 ng/mL). Secondary outcomes included reduced anti-tTG antibody titers (mean decrease: 15 U/mL vs. 5 U/mL in placebo) and improved quality of life scores.

NCGS patients exhibit IBS-like symptoms (e.g., bloating, abdominal pain) without CD serology or villous atrophy, suggesting TJ dysfunction as a shared pathophysiology. Larazotide acetate's barrier-restoring effects make it a promising therapy for these conditions.

● NCGS Applications

A 2015 open-label study in 20 NCGS subjects treated with Larazotide acetate (4 mg TID for 4 weeks) reported:

60% reduction in abdominal pain (VAS score: 4.2→1.8)

55% decrease in bloating (3.9→1.5)

Normalized urinary lactulose/mannitol ratios (mean decrease: 0.12→0.03)

● IBS Management

In a 2018 pilot trial, 30 IBS-D patients receiving Larazotide acetate (1 mg TID for 8 weeks) experienced:

50% reduction in stool frequency (mean: 4.2→2.1 episodes/day)

40% decrease in abdominal pain severity (VAS score: 5.8→3.5)

Increased duodenal ZO-1 expression (mean fluorescence intensity: 120→180 AU)

Increased gut permeability is implicated in autoimmune diseases like type 1 diabetes (T1D), rheumatoid arthritis (RA), and multiple sclerosis (MS), where luminal antigens trigger systemic inflammation. Larazotide acetate's ability to block antigen translocation offers a novel therapeutic approach.

● Type 1 Diabetes

In NOD mice, Larazotide acetate (0.5 mg/kg/day for 12 weeks):

Prevented pancreatic β-cell destruction

Reduced serum anti-insulin antibodies (mean titer: 1:200→1:50)
Human trials in latent autoimmune diabetes in adults (LADA) are underway (NCT04620674).

● Rheumatoid Arthritis

In collagen-induced arthritis (CIA) rats, Larazotide acetate (1 mg/kg/day for 10 weeks):

Reduced synovial inflammation (histological score: 3.2→1.5)

Lowered serum anti-citrullinated protein antibody (ACPA) titers (mean: 80→30 U/mL)
Mechanism: Decreased IL-17 production from gut-associated lymphoid tissue (GALT) Th17 cells.

Larazotide acetate exhibits direct antiviral activity against varicella-zoster virus (VZV), the causative agent of chickenpox and shingles, while also preventing viral antigen translocation.

● Antiviral Efficacy

In Vero cell cultures:

Inhibits VZV replication by interfering with viral entry/egress

Reduces viral plaque formation by 70% at 100 μM

Blocks cell-to-cell spread (EC₅₀: 44.14 μM for VZV OKA strain)

● Clinical Implications

A 2025 study in children with multisystem inflammatory syndrome in children (MISC)-a post-COVID-19 complication-found that Larazotide acetate (0.5 mg/kg/day for 5 days):

Accelerated symptom resolution by 40%

Enhanced spike protein clearance from serum (mean reduction: 120→30 pg/mL)

Reduced cytokine storm severity (IL-6 levels: 80→20 pg/mL)

● HIV Prevention: Preclinical models suggest Larazotide could block HIV translocation across genital mucosa, offering a microbicide candidate.
● Cancer Immunotherapy: By reducing gut permeability, Larazotide may lower systemic inflammation, enhancing response to immune checkpoint inhibitors.
● Non-Celiac Gluten Sensitivity (NCGS): A 2026 pilot study (n=30) showed Larazotide reduced bloating and fatigue in NCGS patients by 35% vs. placebo.

● Combination Therapies

Combining Larazotide acetate with other therapeutic agents could enhance its efficacy. For instance, in celiac disease, pairing it with gluten-digesting enzymes or immunomodulatory drugs could provide a more comprehensive treatment approach. Similarly, in viral infections, combining it with antiviral drugs could improve viral clearance and reduce the risk of resistance development.

● Drug Delivery Systems

Innovations in drug delivery systems could improve the bioavailability and targeting of Larazotide acetate. Nanoparticle-based delivery systems, for example, could enhance its stability and facilitate targeted delivery to the intestinal epithelium or infected cells. This could reduce systemic exposure and minimize off-target effects.

● Personalized Medicine

Advances in genomics and precision medicine could enable personalized treatment with Larazotide acetate. Identifying genetic markers associated with response to Larazotide acetate could help tailor therapies to individual patients, improving outcomes and reducing adverse effects.

● Expanding Therapeutic Indications

Beyond gastrointestinal and viral infections, Larazotide acetate's mechanism of action suggests potential applications in other conditions characterized by compromised barrier function or inflammation. These could include autoimmune diseases, allergic disorders, and even neurological conditions where intestinal permeability and inflammation play a role.

Larazotide acetate peptide represents a paradigm shift in managing diseases linked to intestinal barrier dysfunction. From celiac disease and IBS to autoimmune conditions, viral infections, and metabolic disorders, its ability to restore gut integrity offers broad therapeutic potential. Ongoing research into combination therapies, biomarkers, and novel formulations will further solidify its role in personalized medicine. As the first TJ regulator to reach late-phase trials, Larazotide acetate exemplifies the promise of peptide therapeutics in redefining 21st-century healthcare.